linkedin

Press Releases

Press Releases

Samsung Biologics Reports First Quarter 2022 Financial Results

 

 

·         Q1’22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. 

·         Q1’22 operating profit of KRW 176.4 billion increased 137% compared to Q1’21. 

·         Stable business operations and utilization rates across Plants 1, 2, and 3.

·         Proactive investments into long-term growth, capacity, and sustainability.

 

Incheon, S. Korea, April 27, 2022 – Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization, today announced strong financial results for the first quarter of fiscal year 2022.

 

John Rim, CEO of Samsung Biologics, stated, “Samsung Biologics’ strong start to the 2022 fiscal year was driven by building momentum around our long-term growth strategy and expanding capacity. Our first-quarter financial performance demonstrates a significant and sustained level of customer demand in our services and capabilities. Turning to the present and future, Samsung Biologics has also committed to making sustainability a key component of the way we work and engage with our partners and communities. In our mission to build a healthier future for all while creating enduring and sustainable value, we are investing in initiatives to mitigate the risks of climate change in the greater areas we impact.”

 

 

FIRST QUARTER 2022 RESULTS

 

Samsung Biologics demonstrated strong operational excellence and business agility in the first quarter with earnings exceeding initial projections. 

 

First quarter 2022 revenue was KRW 511.3 billion, an increase of 96% from KRW 260.8 billion reported for the first quarter in the previous year, attributable to the expansion of product sales and the increasing exchange rates amid stable operations of Plants 1, 2, and 3.

 

First quarter 2022 operating profit was KRW 176.4 billion, 137% higher than the prior-year period due to steady sales growth and an increase in the operating rate at Plant 3.

 

First quarter 2022 net profit reached KRW 146.9 billion, an increase of KRW 85.9 billion from KRW 61.0 billion in the first quarter a year ago, and first quarter 2022 operating margin was 35%.

 

 

[KRW billion]

 

Q1’22

Q1’21

YoY Change

Revenues

511.3

260.8

+96%

Operating Profit

176.4

74.3

+137%

PBIT

198.5

79.8

+149%

Net Profit

146.9

61.0

+141%

 

 

FISCAL YEAR 2022 OUTLOOK

 

Samsung Biologics’ Plant 4 construction is expected to be partially operational by October 2022 to support 6 X 10KL production capacity. Upon its full completion in mid-2023six months ahead of schedulethe combined capacity of all plants is expected to total 620KL, the world’s largest biomanufacturing capacity at a single site.

 

As part of its future growth plan, the company is also in the process of securing an additional 350,000m2 of land for its second Bio Campus, which will be 30% larger than the size of the current site. 

 

Alongside our focus on growth and expansion, Samsung Biologics will continue to prioritize its ESG commitments by investing in practices and technologies that will reduce and potentially eliminate GHG emissions, while participating in various climate change initiatives, such as the Sustainable Markets Initiative, in the lead up to COP27.

 

Samsung Biologics will also be closely monitoring, identifying, and providing data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) initiative with Task Force on Climate-Related Financial Disclosures (TCFD) to determine risks and opportunities on climate change as well as the financial impact to translate these data into actions.

 

For more details on performance and financials, please refer to the Earnings Release.

 

 

 

·         Q1’22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. 

·         Q1’22 operating profit of KRW 176.4 billion increased 137% compared to Q1’21. 

·         Stable business operations and utilization rates across Plants 1, 2, and 3.

·         Proactive investments into long-term growth, capacity, and sustainability.

 

Incheon, S. Korea, April 27, 2022 – Samsung Biologics (KRX: 207940.KS), the world’s leading contract development and manufacturing organization, today announced strong financial results for the first quarter of fiscal year 2022.

 

John Rim, CEO of Samsung Biologics, stated, “Samsung Biologics’ strong start to the 2022 fiscal year was driven by building momentum around our long-term growth strategy and expanding capacity. Our first-quarter financial performance demonstrates a significant and sustained level of customer demand in our services and capabilities. Turning to the present and future, Samsung Biologics has also committed to making sustainability a key component of the way we work and engage with our partners and communities. In our mission to build a healthier future for all while creating enduring and sustainable value, we are investing in initiatives to mitigate the risks of climate change in the greater areas we impact.”

 

 

FIRST QUARTER 2022 RESULTS

 

Samsung Biologics demonstrated strong operational excellence and business agility in the first quarter with earnings exceeding initial projections. 

 

First quarter 2022 revenue was KRW 511.3 billion, an increase of 96% from KRW 260.8 billion reported for the first quarter in the previous year, attributable to the expansion of product sales and the increasing exchange rates amid stable operations of Plants 1, 2, and 3.

 

First quarter 2022 operating profit was KRW 176.4 billion, 137% higher than the prior-year period due to steady sales growth and an increase in the operating rate at Plant 3.

 

First quarter 2022 net profit reached KRW 146.9 billion, an increase of KRW 85.9 billion from KRW 61.0 billion in the first quarter a year ago, and first quarter 2022 operating margin was 35%.

 

 

[KRW billion]

 

Q1’22

Q1’21

YoY Change

Revenues

511.3

260.8

+96%

Operating Profit

176.4

74.3

+137%

PBIT

198.5

79.8

+149%

Net Profit

146.9

61.0

+141%

 

 

FISCAL YEAR 2022 OUTLOOK

 

Samsung Biologics’ Plant 4 construction is expected to be partially operational by October 2022 to support 6 X 10KL production capacity. Upon its full completion in mid-2023six months ahead of schedulethe combined capacity of all plants is expected to total 620KL, the world’s largest biomanufacturing capacity at a single site.

 

As part of its future growth plan, the company is also in the process of securing an additional 350,000m2 of land for its second Bio Campus, which will be 30% larger than the size of the current site. 

 

Alongside our focus on growth and expansion, Samsung Biologics will continue to prioritize its ESG commitments by investing in practices and technologies that will reduce and potentially eliminate GHG emissions, while participating in various climate change initiatives, such as the Sustainable Markets Initiative, in the lead up to COP27.

 

Samsung Biologics will also be closely monitoring, identifying, and providing data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) initiative with Task Force on Climate-Related Financial Disclosures (TCFD) to determine risks and opportunities on climate change as well as the financial impact to translate these data into actions.

 

For more details on performance and financials, please refer to the Earnings Release.

 ​

SITE MAP

close
Close

Thank you for Subscribing to Our Newsletter

아래 다운로드 버튼을 클릭하시면 바로 다운로드 하실 수 있습니다.

Close

Subscribe to Our Newsletter

파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.

Subscribe to Our Newsletter
    • - 개인정보 수집 목적 : 이메일 발신서비스 제공
    • - 개인정보 수집 항목 : 이메일 주소, 회사명, 이름, 직급, 국가
    • - 이용 및 보관 기간 : 이메일 발신서비스 해지 시까지

    개인정보 수집에 동의하지 않을 시, 뉴스레터 서비스를 이용할 수 없습니다.

    삼성바이오로직스 개인정보 보호정책에 따라 개인정보는 안전하게 관리됩니다.

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved